Niels van de Donk

PROF.DR., (Principal Investigator)


Research output per year

If you made any changes in Pure these will be visible here soon.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)

Landgren, C. O., Chari, A., Cohen, Y. C., Spencer, A., Voorhees, P., Estell, J. A., Sandhu, I., Jenner, M. W., Williams, C., Cavo, M., van de Donk, N. W. C. J., Beksac, M., Moreau, P., Goldschmidt, H., Kuppens, S., Bandekar, R., Clemens, P. L., Neff, T., Heuck, C., Qi, M. & 1 others, Hofmeister, C. C., 1 Jan 2020, In : Leukemia.

Research output: Contribution to journalArticleAcademicpeer-review

Open Access

Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma

Holthof, L. C., van der Horst, H. J., van Hal-van Veen, S. E., Ruiter, R. W. J., Li, F., Buijze, M., Andersen, M. N., Yuan, H., de Bruijn, J., van de Donk, N. W. C. J., Lokhorst, H. M., Zweegman, S., Groen, R. W. J. & Mutis, T., 1 Jan 2020, In : Haematologica. 105, 2, p. e80-e83

Research output: Contribution to journalLetterAcademicpeer-review

Open Access

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Moreau, P., Attal, M., Hulin, C., Arnulf, B., Belhadj, K., Benboubker, L., Béné, M. C., Broijl, A., Caillon, H. L., Caillot, D., Corre, J., Delforge, M., Dejoie, T., Doyen, C., Facon, T., Sonntag, C. C., Fontan, J., Garderet, L., Jie, K-S., Karlin, L. & 38 others, Kuhnowski, F., Lambert, J. R., Leleu, X., Lenain, P., Macro, M., Mathiot, C., Orsini-Piocelle, F., Perrot, A., Stoppa, A-M., van de Donk, N. W. CJ., Wuilleme, S., Zweegman, S., Kolb, B., Touzeau, C., Roussel, M., Tiab, M., Marolleau, J-P., Meuleman, N., Vekemans, M-C., Westerman, M., Klein, S. K., Levin, M-D., Fermand, J. P., Escoffre-Barbe, M., Eveillard, J-R., Garidi, R., Ahmadi, T., Zhuang, S., Chiu, C., Pei, L., de Boer, C., Smith, E., Deraedt, W., Kampfenkel, T., Schecter, J., Vermeulen, J., Avet-Loiseau, H. & Sonneveld, P., 6 Jul 2019, In : The Lancet. 394, 10192, p. 29-38

Research output: Contribution to journalArticleAcademicpeer-review

Carfilzomib for relapsed and refractory multiple myeloma

Groen, K., van de Donk, N., Stege, C., Zweegman, S. & Nijhof, I. S., 2019, In : Cancer management and research. 11, p. 2663-2675 13 p.

Research output: Contribution to journalReview articleAcademicpeer-review

CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia

Naik, J., Themeli, M., de Jong-Korlaar, R., Ruiter, R. W. J., Poddighe, P. J., Yuan, H., de Bruijn, J. D., Ossenkoppele, G. J., Zweegman, S., Smit, L., Mutis, T., Martens, A. C. M., van de Donk, N. W. C. J. & Groen, R. W. J., 28 Feb 2019, In : Haematologica. 104, 3, p. e100-e103

Research output: Contribution to journalLetterAcademicpeer-review

Open Access